Compound fluorouracil injection

Fluorouracil is first converted into 5-fluoro-2-deoxyuridine nucleotide in the body, which inhibits thymine nucleotide synthetase, blocking the conversion of deoxyuridine nucleotide into deoxythymine nucleotide, thereby inhibiting DNA biosynthesis. In addition, it can also be incorporated into RNA, inhibiting RNA synthesis by preventing uracil and orotic acid from incorporating into RNA. Fluorouracil is a cell cycle-specific drug that mainly inhibits S-phase tumor cells. Ginseng polysaccharides have a promoting effect on the body's immune function.

This product is a compound preparation, and its components are: each tube contains 40mg of fluorouracil and 40mg of ginseng polysaccharide. Excipients are: refined soybean lecithin, cholesterol, polysorbate 80, vitamin E, oleic acid, povidone K30, disodium hydrogen phosphate, and sodium dihydrogen phosphate.

This product is a milky white or light yellow suspension liquid. If it separates into layers after standing, it should still be a uniform suspension after shaking.

Used for the treatment of digestive tract cancer (colon cancer, rectal cancer, gastric cancer), breast cancer, primary liver cancer and other cancers.

Intravenous drip. The initial dose is 80 mg/day, and then the dose is gradually increased. The maximum dose is generally not more than 160 mg/day. Add it to 500 ml of normal saline and drip it intravenously. The drip rate should not exceed 60 drops per minute, once a day. The total amount of one course of treatment is 3-4 g calculated according to fluorouracil. After one course of treatment, rest for 1-2 weeks and continue the second course of treatment. Surgical patients: Start maintenance medication 2 weeks after surgery, 120-160 mg/time, twice a week.

1. Nausea, loss of appetite or vomiting, usually not serious with the dose, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea are occasionally seen. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the treatment, and returns to normal after about 3 to 4 weeks), thrombocytopenia is rare. Cough, shortness of breath or cerebellar ataxia are extremely rare. 2. Long-term use can lead to nervous system toxicity and bone marrow suppression. 3. Occasionally myocardial ischemia after medication, angina pectoris and electrocardiogram changes may occur.

1. It is contraindicated when accompanied by chickenpox or herpes zoster. 2. It is contraindicated for women within 3 months of early pregnancy.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Women are prohibited from using this product within 3 months of early pregnancy, and breastfeeding is prohibited during the use of this product. Precautions for the elderly: Not yet clear.

It has been reported that a variety of drugs can biochemically affect the anti-cancer effect or toxicity of fluorouracil, common drugs include methotrexate, methionine and tetrahydrofolate. When used in combination with methotrexate, fluorouracil should be given 4 to 6 hours after methotrexate, otherwise the effect will be reduced. Giving tetrahydrofolate first and then fluorouracil can increase its efficacy. This product can generate a neurotoxic metabolite - fluorocitric acid, which can cause cerebral palsy, so it cannot be injected intrathecally. Allopurinol can reduce the bone marrow suppression caused by fluorouracil.

Keep in a dark, airtight container in a cool and dark place (not exceeding 20°C).

10ml:40mg (fluorouracil)

Tentative 24 months

Shenyang Yaoda Leiyunshang Pharmaceutical Co., Ltd.

• Founded in:

  1998-09-16

• Address:

  No. 111 Xianghuai Road, Benxi Economic and Technological Development Zone, Liaoning Province

• Tax NO.:

  91210500711133379A

• Registered Funds:

  30.8 million yuan

• Website:

  Log in to view

• Email:

  Log in to view